Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Get a high-probability setup with clear entry and exit points right here. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the risk of cardiovascular events. Now the Danish company is hoping to score ...

Novo Nordisk (NVO) stock plunges 44% YoY, hitting a 52-week low as bearish signals pile up. New obesity drug deal fails to excite investors, with Eli Lilly’s rival treatment set to launch first.